RxDoctor Payments Data

Richard Dechamplain, MD

Ophthalmology · Georgetown, SCNPI 1154343192

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 10 payments — averaging $194.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Kala Pharmaceuticals, Inc.$232
  • Biotissue Holdings Inc.$102
  • The Cameron-ehlen Group, Inc.$59
  • Alcon$17

What the payments were for

  • Consulting fees$1,40072%
  • Food & beverage$54528%

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bausch & Lomb Americas Inc.3$1,535
Kala Pharmaceuticals, Inc.2$232
Biotissue Holdings Inc.3$102
The Cameron-ehlen Group, Inc.1$59
Alcon1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,945 in reported general payments places this provider in the 45th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$691,135
Medicare patients
1,611
Services billed
4,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost93$37,706
RestasisCyclosporine28$36,152
Prednisolone Acetate598$30,439
XiidraLifitegrast23$22,891
VyzultaLatanoprostene Bunod35$16,063
CombiganBrimonidine Tartrate/Timolol23$10,859
TyrvayaVarenicline Tartrate13$8,456
RocklatanNetarsudil Mesylat/Latanoprost12$3,980
Latanoprost323$3,723
Lotemax SmLoteprednol Etabonate12$3,015
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,963
Ketorolac Tromethamine132$2,679
Travoprost13$2,636
Difluprednate18$2,174
Ofloxacin131$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,535$38,95458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Georgetown

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →